What is Elio?
Elio is an innovative technology firm that is fundamentally transforming the landscape of microscopy. By integrating adaptive optics with AI-powered interpretation, the company provides a platform that enables researchers to observe biological samples in real-time without the need for traditional labeling methods. This approach not only enhances the accuracy of biological insights but also significantly increases the efficiency of laboratory workflows. Elio targets a diverse range of scientific institutions and commercial laboratories that require high-fidelity, dynamic data to advance their understanding of complex biological processes. The company's market position is defined by its ability to bridge the gap between raw imaging data and actionable scientific intelligence, making it a key player in the next generation of life science instrumentation.
How much funding has Elio raised?
Elio has raised a total of $21M across 1 funding round:
Series A
$21M
Series A (2026): $21M with participation from Scribble Ventures, UpWest, Xora Innovation, Resolute.Vc, and Innovation Endeavors
Key Investors in Elio
Scribble Ventures
Scribble Ventures is a venture capital firm focused on investing in pre-seed and seed stage AI-native companies, providing hands-on support in product development and go-to-market strategies.
UpWest
UpWest is a venture firm that funds, fast-tracks, and supports Israeli founders as they enter the US market, specializing in leading early-stage rounds to drive rapid growth.
Xora Innovation
Xora provides capital and support to deep tech entrepreneurs, with a specific focus on AI in physical industries and the infrastructure of tomorrow.
What's next for Elio?
With the successful closure of this major strategic investment, Elio is well-positioned to execute its next phase of growth, which focuses on scaling its enterprise-level operations and deepening its AI capabilities. The company is expected to prioritize the commercialization of its microscopy platform, targeting key research hubs that are currently underserved by traditional imaging technologies. Furthermore, the strategic backing from its investor syndicate provides Elio with the necessary resources to navigate the complexities of the life sciences market, including regulatory milestones and international expansion. As the company continues to refine its algorithms and hardware, it is likely to become an indispensable partner for organizations seeking to modernize their research infrastructure through data-driven, intelligent microscopy solutions.
See full Elio company page
